Rowse A D, Morrison M J, Scott P H, Banks A J, Roginski C
Oncology. 1982;39(5):287-91. doi: 10.1159/000225653.
When surgery fails to cure breast cancer it is due to disseminated micrometastases present at the time of operation. The measurement of urinary hydroxyproline (OHP) is a possible screening test for such metastases in bone. This study compared both a single and serial urinary OHP estimation with the axillary node status, the bone scan status and the subsequent clinical course. A single measurement did not correlate with the axillary node or bone scan status, neither was there a relationship with the subsequent clinical course. Serial OHP estimations, every 3 months for a year, increased the accuracy of the test such that node-positive patients had higher excretions than node-negative patients (p less than 0.05). Patients who subsequently died with bone metastases tended to have a higher excretion than those who remained disease free, although this did not reach statistical significance. No relationship existed between serial OHP estimations and bone scan status. We consider the measurement of urinary OHP to be insufficiently sensitive to detect bone micrometastases and it is only raised when a substantial amount of bone is involved.
手术未能治愈乳腺癌是因为手术时存在播散性微转移。尿羟脯氨酸（OHP）的测定可能是对骨转移进行筛查的一种检测方法。本研究将单次及连续尿OHP测定结果与腋窝淋巴结状态、骨扫描状态及后续临床病程进行了比较。单次测定与腋窝淋巴结或骨扫描状态均无相关性，与后续临床病程也无关系。连续1年每3个月进行一次OHP测定提高了检测的准确性，使得淋巴结阳性患者的排泄量高于淋巴结阴性患者（p<0.05）。随后死于骨转移的患者排泄量往往高于无疾病进展的患者，尽管这未达到统计学意义。连续OHP测定与骨扫描状态之间无相关性。我们认为尿OHP测定对检测骨微转移的敏感性不足，只有在大量骨质受累时才会升高。
